(Q42581589)

3 November 2017

0 references

Risperidone for schizophrenia (English)

1 reference

3 November 2017

1 reference

1 reference

Edwards JG

1

1 reference

PMC publication ID

2540264

3 November 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

3 November 2017

1 reference

3 November 2017

308

1 reference

3 November 2017

6940

1 reference

3 November 2017

1311-1312

1 reference

Survey on the pharmacodynamics of the new antipsychotic risperidone

3 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Biochemical profile of risperidone, a new antipsychotic

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Risperidone: clinical safety and efficacy in schizophrenia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2540264

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

28 May 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/7517246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/7517246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/BMJ.308.6940.1311

1 reference

3 November 2017

1 reference

PMC publication ID

2540264

3 November 2017

PubMed publication ID

7517246

1 reference

PMC publication ID

2540264